SEPNSepterna, Inc.
$38.32+144% 1Y
$38.32
$16.0052 weeks$48.13
SEPN in its own filings
Nothing in SEPN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
43
Events found in the filings · across 168 filings · the record starts in 2024
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 25, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 5, 2024
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity6 occurrences
- 2024-10-22
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 25, 2026Effective August 24, 2026, the Company’s Board of Directors appointed Rajiv Patni, M.D., as the Company’s Chief Medical Officer.Regulation FD disclosure · Form 8-K
- Aug 10, 2026Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 11, 2026Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results.Earnings release · press release
- Apr 13, 2026Septerna Announces Initiation of Phase 1 Clinical Trial of.Regulation FD disclosure · press release
- Mar 9, 2026Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Mar 2, 2026On March 1, 2026, the Company announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modulator (“NAM”) of Mas-related G protein-coupled receptor X2 (“MRGPRX2”), and outlined initial Phase 2 development strategy.Regulation FD disclosure · Form 8-K
- Jan 12, 2026Healthcare Conference 2026 January 2026 Nasdaq: SEPN.Regulation FD disclosure · press release
- Jan 8, 2026Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer.Regulation FD disclosure · press release
- Nov 10, 2025Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Sep 29, 2025On September 25, 2025 (the “Appointment Date”), the Board of Directors (the “Board”) of Septerna, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Keith Gottesdiener, M.D. to serve as a member of the Board and as a Class I director, to hold office for a three-year term …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry